

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 86098

**Title:** Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02684216

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-06-01

**Reviewer chosen by:** Geng-Long Liu (Quit 2023)

**Reviewer accepted review:** 2023-08-09 10:25

**Reviewer performed review:** 2023-08-14 02:10

**Review time:** 4 Days and 15 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection

<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

The comments are include within the text of manuscript. Major revision is required by the authors.

1 It seems that the authors have not performed the stem cells check up in the patients before, applying the autologous stem cell transplantation.

Application of stem cell profile at single cell level is required.

Besides mentioning the type of stem cell is required.

At single cell level.

2 In neoplastic disorders, newly diagnosed is also late diagnosis. Since the initiation of the primary event, it takes very long time (approximately 10 years up to the initial medical check-up, including diagnostic period.

3 Please include the complete spelling of CSF at the initial line here.

4 Circulating lymphoid cells by only 2ml peripheral blood of patient's blood is absolutely non-invasive.

5 Circulating .Tnmor DNA dooes not last adequate duration in the blood stream. .Therefore, the achieved results may be challenging.

6 Therapeutic

7 the complete

8 There is no sign of single cell based analysis

What is the ID- for biological status of lymphoma in the target patients?

What about proliferative index including Ki-67 or PCNA? What about other proteins including Cyclins D1, E and B1?

These are required at pre-treatment procedure.

Upon the provided items, formalin degrade the nature of proteins

9 Regarding formaline, there is a challenging condition for protein analytical procedure.

10 Is there any result available?

11 Require revision

12 The traced gene or genes are required to be mentioned.

13 Reision is required: The patient then received whole-brain radiotherapy (WBRT, 30GY) combined with temozolomide and Zanubrutinib, got a practical radiographic response and still under treatment now. Patient (P8) demonstrated a partial radiographic response, and the CSF mutant allele frequency of which dramatically decreased other than gene fusion of ABL1 BCR-ABL1 (Figure 5).

14 Is not clear: HD-MTX delayed excretion, changing regimen as rituximab, Zanubrutinib and lenalidomide, there was no treatment-related death.

15 Is not clear enough: still half of patients relapsed, and 5-year survival rates was only 30-40%.<sup>[3]</sup> Studies show

16 Requires revision: was not reached in this study in 14.7 months

17 Hematopoietic disorders, including malignancies

18 In hematopoietic disorders, application of cytogenetics study is required.

19 Requires revision: no non-hematological toxicities in grade 4 happened.

20 Design and categorization of patients was unclear. Methodology of this manuscript is required to be revised. The sequencing results are required to be approved by protein expression analysis.



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The non-related items to the the provided title, is required to be excluded from the text.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 86098

**Title:** Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02684216

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-06-01

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2023-09-05 17:28

**Reviewer performed review:** 2023-09-08 07:34

**Review time:** 2 Days and 14 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection

<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### SPECIFIC COMMENTS TO AUTHORS

Dear Author, Cancer is complex and requires the following considerations: 1. Pedigree-based Analysis; 2. Single Cell based with very high enumeration; 3. relevant molecular based analysis; 4. applying the correlative and sequential based manner for unmasking the course of evolution. Otherwise the Scientific approach will be descriptive; I.e.,  $2 \times 2 = 4$ . Best wishes